Peer-Reviewed Publications


Peer-Reviewed Publications

Peer-Reviewed Publications

1. Suck G, Linn YC, Tonn T. Natural Killer Cells for Therapy of Leukemia. Transfus Med Hemother. 2016 Mar;43(2):89-95. doi: 10.1159/000445325. Epub 2016 Mar 22.

2.Genßler S, Burger MC2, Zhang C, Oelsner S, Mildenberger I, Wagner M, Steinbach JP, Wels WS. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2015 Dec 21;5(4):e1119354. eCollection 2016.

3. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012 May;53(5):958-65. doi: 10.3109/10428194.2011.634048. Epub 2011 Dec 6.

4. Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso JC 3rd, Kaur B, Caligiuri MA, Yu J. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. 2015 Jul 9;5:11483. doi: 10.1038/srep11483.

5. Anikeeva N, Steblyanko M, Fayngerts S, Kopylova N, Marshall DJ, Powers GD, Sato T, Campbell KS, Sykulev Y. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol. 2014 Aug;44(8):2331-9. doi: 10.1002/eji.201344179. Epub 2014 Jun 5.

6. Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells.
Klingemann H, Boissel L, Toneguzzo F.
Front Immunol. 2016 Mar 14;7:91. doi: 10.3389/fimmu.2016.00091. eCollection 2016. Review.

7. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T.
J Cell Mol Med. 2016 Mar 23. doi: 10.1111/jcmm.12810. [Epub ahead of print]

8. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy.
Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T.
Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11.

9. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.
Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K.
Neuro Oncol. 2016 Jan 26. pii: nov318. [Epub ahead of print]

10. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS.
J Natl Cancer Inst. 2015 Dec 6;108(5). pii: djv375. doi: 10.1093/jnci/djv375. Print 2016 May.

11. Challenges of cancer therapy with natural killer cells.
Klingemann H.
Cytotherapy. 2015 Mar;17(3):245-9. doi: 10.1016/j.jcyt.2014.09.007. Epub 2014 Dec 18. Review.

12. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.
Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.

13. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.
Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

14. Are natural killer cells superior CAR drivers?
Klingemann H.
Oncoimmunology. 2014 Apr 15;3:e28147. eCollection 2014.

15. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H.
Oncoimmunology. 2013 Oct 1;2(10):e26527. Epub 2013 Oct 22.

16. Treatment of patients with advanced cancer with the natural killer cell line NK-92.
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G.
Cytotherapy. 2013 Dec;15(12):1563-70. doi: 10.1016/j.jcyt.2013.06.017. Epub 2013 Oct 1.

17. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
Sahm C, Schönfeld K, Wels WS.
Cancer Immunol Immunother. 2012 Sep;61(9):1451-61. doi: 10.1007/s00262-012-1212-x. Epub 2012 Feb 5.

18. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

19.Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H.
Leuk Res. 2009 Sep;33(9):1255-9. doi: 10.1016/j.leukres.2008.11.024. Epub 2009 Jan 14.

20. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H.
Cytotherapy. 2008;10(6):625-32. doi: 10.1080/14653240802301872.

21. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS.
Cancer Immunol Immunother. 2008 Mar;57(3):411-23. Epub 2007 Aug 24.

22. Prevention of Ctl and Nk Cell-Mediated Cytotoxicity by Microencapsulation.
Soon-Shiong P, Lu ZN, Grewal I, Lanza R, Clark W.
Horm Metab Res Suppl 1990; 25: 215-9.